migraine treatment
Japan’s Shin Nippon Biomedical Labs to buy US-based Satsuma for nasal powder migraine drug
Developed by Satsuma, STS101 is a nasal powder formulation of the anti-migraine drug, dihydroergotamine mesylate.
Japan’s Shin Nippon Biomedical Labs to buy US-based Satsuma for nasal powder migraine drug
Developed by Satsuma, STS101 is a nasal powder formulation of the anti-migraine drug, dihydroergotamine mesylate.
Drug approvals boost Japanese migraine treatment online
Some players have been highly active in digital channels of various countries.
Most Read
1. NUH to establish health centre for early cancer detection in 2025 2. KPMG's Guillaume Sachet on navigating healthcare’s evolution: Cross-border collaboration crucial to fostering trusted AI, innovation 3. Why rare disease policies are critical to ensure equitable access to treatment for rare disease communities in Southeast Asia 4. 3 in 5 novice nurses struggle with higher-complexity procedures 5. SGH and NNI study reveals connection between scoliosis and brainstemResource Center
Read Here
Advertise
Sign Up
Event News
Event News
Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi
![Discover cutting-edge strategies reshaping healthcare delivery with EY’s Abhay Bangi]()
Co-Written / Partner
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
Explore the complexities of the healthcare landscape, as well as innovation and transformation within the sector, guided by the EY expert’s visionary insights.
